{"schema_version":"secwatch.filing_event.v1","accession":"0001384101-24-000064","form_type":"8-K","ticker":"VCYT","cik":"0001384101","company_name":"VERACYTE, INC.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.183349+00:00","generated_at":"2026-06-02T17:12:56.024858+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Veracyte Q1 revenue $96.8M (+17%), testing revenue +25%, net loss narrows 77%","bullets":["Total revenue $96.8M (up 17% YoY); testing revenue $90.3M (up 25%) led by Decipher Prostate and Afirma.","Net loss improved 77% to $1.9M ($0.02 per share) from $8.3M loss in Q1 2023.","Non-GAAP gross margin held at 68%; non-GAAP op expenses grew 6% to $61.6M.","Decipher Prostate received highest NCCN rating; contracted with large commercial payer covering ~30M members.","Completed C2i Genomics acquisition for MRD testing; initiated bladder cancer MRD test; cash $209.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001384101-24-000064","json":"https://secwatch.observer/filing/0001384101-24-000064.json","markdown":"https://secwatch.observer/filing/0001384101-24-000064.md","text":"https://secwatch.observer/filing/0001384101-24-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1384101/000138410124000064/0001384101-24-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1384101/000138410124000064/vcyt-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T17:12:56.024858+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"579221a3dca9f9c19549221be62c03864e0d3d1b","claim":"VERACYTE, INC. reported first quarter ended March 31, 2024 results: revenue $96.8 million, net income $1.9 million, EPS $0.02.","evidence_excerpt":"EX-99.1 (EX-99.1 PRESS RELEASE 05.07.2024) --- PRESS RELEASE 05.07.2024 Document Exhibit 99.1 Veracyte Announces First Quarter 2024 Financial Results Grew total revenue to $96.8 million, an increase of 17% Grew testing revenue by 25% Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 7, 2024 --- Veracyte, Inc. (Nasdaq: VCYT) today","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1384101/000138410124000064/0001384101-24-000064-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$96.8 million"},{"label":"Net income","value":"$1.9 million"},{"label":"EPS","value":"$0.02"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}